Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities
Please select the market sector you are interested in.
Please select the university you are interested in.
Show only Easy Access opportunities.
Narrow your search with a few keywords.
University: University of Glasgow
Sector(s): Healthcare & Pharmaceuticals, Life Sciences
Improving suicide-gene therapy for the treatment of cancer.
The University of Glasgow has developed a telomerase targeted adenoviral suicide-gene therapy vector (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.
Suicide-gene therapy aims to selectively target cancer cells without harming normal cells thus reducing the toxicity associated with conventional therapies.
To achieve this selectivity, gene therapy approaches require mechanisms to regulate and limit the expression of therapeutic genes to cancer cells .Achieving this aim remains a challenge for the development of clinically useful suicide gene-therapy.
In-vitro/in-vivo experiments against ovarian cancer cells have confirmed that this construct provides efficient cancer cell kill whilst minimising harmful effects on normal cells.
Tumour-specific gene promoters can be used for transcriptional targeting to improve selectivity and increase therapeutic index. However until recently this has been difficult as many tumour specific promoters show weak transcriptional activity and are unable to drive efficient expression of the therapeutic gene. In addition, the promoter activity is often restricted to one tumour type for example HER2/NEU positive is limited to use with breast cancer.
This technology is available as an Easy Access deal, available to companies and individuals to license for FREE.
Easy Access Documents:
Please enter your name.
Please enter the name of the company you work for.
Is your company an SME?
Please select the country you are in.
Please select what part of the UK you are in.
Please select from the following options.
Please enter your email address.
Please enter your telephone number.
To help us process your enquiry faster please enter some details about the information you are interested in.
Please prove you are a human by completing this simple image recognition task.
Using visible light and low cost naturally occuring photocatalyst materials, Heriot-Watt University has developed a process for producing Silver nanoparticles on flexible polyimide film.
We now seek commercial partners in Antibacterials & Healthcare or flex/ flex-rigid PCB manufacture who can de...
The University of Glasgow has developed novel Cardiac Imaging software to be used in existing Cardiac MRI equipment, automating the current process to reduce potential errors.
Researchers at Heriot-Watt have developed a resorbable polymer insert which is capable of releasing over a controlled time (slow release)of antibacterial/ antibiotic drug preparations to prevent, for example, tooth decay or gum disease.
University seek partners who could commercialise this techno...
This technology developed at the University of Aberdeen relates to the discovery of mutation of a single gene in individuals with classical autism. The gene is involved in protein translation and offers possibilities in the diagnostic and therapeutic markets for those with autism spectrum disorder.
This cattle‐specific vaccine delivery system can readily deliver and express antigens against a range of diseases that affect cattle, offering the potential to provide long term immunity and protection. It can also be used to deliver therapeutic proteins to improve productivity in cattle.